[HTML][HTML] Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and …
…, SM Tolaney, CS Kuzma, TJ Pluard… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (…
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (…
[PDF][PDF] Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
…, MS Kavuri, D McEachern, YY Dong, C Ma, T Pluard… - Cell reports, 2013 - cell.com
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome
comparisons with originating breast cancers representative of the major intrinsic …
comparisons with originating breast cancers representative of the major intrinsic …
[HTML][HTML] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
…, PZ New, M Lacroix, SA May, TJ Pluard… - Journal of translational …, 2018 - Springer
Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
…, M Lacroix, SA May, PZ New, TJ Pluard… - JAMA …, 2023 - jamanetwork.com
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
…, I Zoberi, M Taylor, W Gillanders, T Pluard… - The lancet …, 2010 - thelancet.com
Background Treatment with bisphosphonates decreases bone loss and can increase disease-free
survival in patients with breast cancer. The aim of our study was to assess the effect of …
survival in patients with breast cancer. The aim of our study was to assess the effect of …
[HTML][HTML] Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the …
…, L Carey, CX Ma, G Unzeitig, T Pluard… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER)–positive
primary breast cancer triaged to chemotherapy when the protein encoded by the …
primary breast cancer triaged to chemotherapy when the protein encoded by the …
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
…, K Weilbaecher, I Mayer, TJ Pluard… - The Lancet …, 2018 - thelancet.com
Background The CXC chemokine receptor type 4 (CXCR4)–stromal cell-derived factor-1α (SDF-1α)
axis regulates function and trafficking of immune cells and the tumour …
axis regulates function and trafficking of immune cells and the tumour …
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
…, MA Danso, L Popovic, TJ Pluard… - The lancet …, 2019 - thelancet.com
Background Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains immune
cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the immune …
cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the immune …
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash …
…, JT Beck, JA Glaspy, JA Peguero, TJ Pluard… - The Lancet …, 2017 - thelancet.com
Background Stomatitis is a class effect associated with the inhibition of mTOR and is
associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis …
associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis …
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
…, D Tripathy, M Cobleigh, A Forero, TJ Pluard… - Clinical Cancer …, 2017 - AACR
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to
assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/…
assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/…